Inhibrx Biosciences, Inc.
US ˙ NasdaqGS ˙ US45720L1070

Introduction

This page provides a comprehensive analysis of the known insider trading history of Mark Lappe. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Mark Lappe has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
Chief Executive Officer, Director 705,548
US:INBX / Inhibrx Biosciences, Inc. Chief Executive Officer, Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Mark Lappe. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases INBX / Inhibrx Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in INBX / Inhibrx Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

INBX / Inhibrx Biosciences, Inc. Insider Trades
Insider Sales INBX / Inhibrx Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in INBX / Inhibrx Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

INBX / Inhibrx Biosciences, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Mark Lappe as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-09-16 2024-09-16 4 INBX Inhibrx Biosciences, Inc.
Common Stock
P - Purchase 13,037 705,548 1.88 17.13 223,324 12,086,037
2024-09-16 2024-09-12 4 INBX Inhibrx Biosciences, Inc.
Common Stock
P - Purchase 26,963 692,511 4.05 15.05 405,793 10,422,291
2024-09-10 2024-09-10 4 INBX Inhibrx Biosciences, Inc.
Common Stock
P - Purchase 8,500 665,548 1.29 15.19 129,115 10,109,674
2024-09-10 2024-09-09 4 INBX Inhibrx Biosciences, Inc.
Common Stock
P - Purchase 9,500 657,048 1.47 15.21 144,495 9,993,700
2024-09-10 2024-09-06 4 INBX Inhibrx Biosciences, Inc.
Common Stock
P - Purchase 26,000 647,548 4.18 15.29 397,540 9,901,009
2024-09-03 2024-09-03 4 INBX Inhibrx Biosciences, Inc.
Common Stock
P - Purchase 4,712 165,000 2.94 16.31 76,853 2,691,150
2024-09-03 2024-09-03 4 INBX Inhibrx Biosciences, Inc.
Common Stock
P - Purchase 15,288 160,288 10.54 15.66 239,410 2,510,110
2024-09-03 2024-08-30 4 INBX Inhibrx Biosciences, Inc.
Common Stock
P - Purchase 10,000 145,000 7.41 14.02 140,200 2,032,900
2024-09-03 2024-08-29 4 INBX Inhibrx Biosciences, Inc.
Common Stock
P - Purchase 10,000 135,000 8.00 14.03 140,300 1,894,050
2024-08-22 2024-08-21 4 INBX Inhibrx Biosciences, Inc.
Common Stock
P - Purchase 12,945 54,865 30.88 12.93 167,379 709,404
2024-08-22 2024-08-20 4 INBX Inhibrx Biosciences, Inc.
Common Stock
P - Purchase 27,055 41,920 182.00 12.97 350,903 543,702
2024-05-30 2024-05-29 4 INXB Inhibrx Biosciences, Inc.
Common Stock
A - Award 14,865 14,865
2024-05-30 2024-05-29 4 INXB Inhibrx Biosciences, Inc.
Common Stock
A - Award 125,000 125,000
2024-05-30 2024-05-29 4 INXB Inhibrx Biosciences, Inc.
Common Stock
A - Award 621,548 621,548
2024-05-30 2024-05-30 4 INBX Inhibrx, Inc.
Common Stock
D - Sale to Issuer -59,462 0 -100.00 30.00 -1,783,860
2024-05-30 2024-05-30 4 INBX Inhibrx, Inc.
Common Stock
D - Sale to Issuer -500,000 0 -100.00 30.00 -15,000,000
2024-05-30 2024-05-30 4 INBX Inhibrx, Inc.
Common Stock
D - Sale to Issuer -2,486,192 0 -100.00 30.00 -74,585,760
2023-03-01 2023-02-28 4 INBX Inhibrx, Inc.
Common Stock
S - Sale X -60 2,486,192 0.00 25.02 -1,501 62,206,513
2023-01-24 2023-01-24 4 INBX Inhibrx, Inc.
Common Stock
S - Sale X -63 2,486,252 0.00 26.11 -1,645 64,922,753
2023-01-24 2023-01-24 4 INBX Inhibrx, Inc.
Common Stock
S - Sale X -4,272 2,486,315 -0.17 25.71 -109,833 63,923,159
2023-01-24 2023-01-23 4 INBX Inhibrx, Inc.
Common Stock
S - Sale X -21,665 2,490,587 -0.86 25.36 -549,364 63,154,313
2022-12-20 2022-12-19 4 INBX Inhibrx, Inc.
Common Stock
S - Sale X -754 2,512,252 -0.03 26.29 -19,820 66,036,805
2022-12-20 2022-12-19 4 INBX Inhibrx, Inc.
Common Stock
S - Sale X -25,246 2,513,006 -0.99 25.53 -644,624 64,166,341
2022-11-18 2022-11-17 4 INBX Inhibrx, Inc.
Common Stock
S - Sale X -1,150 2,538,252 -0.05 32.38 -37,241 82,197,991
2022-11-18 2022-11-17 4 INBX Inhibrx, Inc.
Common Stock
S - Sale X -912 2,539,402 -0.04 30.67 -27,969 77,878,381
2022-11-18 2022-11-17 4 INBX Inhibrx, Inc.
Common Stock
S - Sale X -6,773 2,540,314 -0.27 30.15 -204,196 76,586,657
2022-11-18 2022-11-17 4 INBX Inhibrx, Inc.
Common Stock
S - Sale X -1,767 2,547,087 -0.07 28.86 -50,991 73,502,308
2022-11-18 2022-11-17 4 INBX Inhibrx, Inc.
Common Stock
S - Sale X -4,333 2,548,854 -0.17 27.45 -118,937 69,964,003
2022-11-18 2022-11-17 4 INBX Inhibrx, Inc.
Common Stock
S - Sale X -4,106 2,553,187 -0.16 26.57 -109,098 67,838,945
2022-11-18 2022-11-17 4 INBX Inhibrx, Inc.
Common Stock
S - Sale X -6,959 2,557,293 -0.27 25.36 -176,477 64,851,928
2022-10-18 2022-10-17 4 INBX Inhibrx, Inc.
Common Stock
S - Sale X -121 2,564,252 0.00 31.51 -3,812 80,792,144
2022-10-18 2022-10-17 4 INBX Inhibrx, Inc.
Common Stock
S - Sale X -2,892 2,564,373 -0.11 30.81 -89,090 78,996,792
2022-10-18 2022-10-17 4 INBX Inhibrx, Inc.
Common Stock
S - Sale X -14,006 2,567,265 -0.54 29.92 -419,123 76,824,121
2022-10-18 2022-10-17 4 INBX Inhibrx, Inc.
Common Stock
S - Sale X -8,981 2,581,271 -0.35 28.66 -257,419 73,985,938
2021-01-19 2021-01-15 4 INBX Inhibrx, Inc.
Stock Option (right to buy)
A - Award 145,000 145,000
2021-01-19 2020-12-28 4 INBX Inhibrx, Inc.
Common Stock
G - Gift 500,000 500,000
2021-01-19 2020-12-28 4 INBX Inhibrx, Inc.
Common Stock
G - Gift -500,000 2,590,252 -16.18
2020-08-18 3 INBX Inhibrx, Inc.
Common Stock
3,090,252
2020-08-18 3 INBX Inhibrx, Inc.
Common Stock
59,462
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)